Compositions comprising bacterial strains

1. A method of reducing an amount of an eosinophil in a tissue with increased eosinophils compared to normal tissue in a subject, comprising administering to the subject a pharmaceutical composition that comprises bacteria strain of the genus Roseburia , wherein the bacteria strain comprises a 16s rRNA gene sequence with at least 99% sequence identity to SEQ ID NO: 3, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and gap extension penalty of 2, in an amount sufficient to reduce the amount of the eosinophil relative to an amount of the eosinophil prior to the administration.

2. The method of claim 1 , wherein the subject has a condition that is characterized by elevated eosinophil levels.

3. The method of claim 2 , wherein the condition is selected from the group consisting of: asthma; arthritis; multiple sclerosis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease; celiac disease; chronic obstructive pulmonary disease (COPD); cancer; uveitis; scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; allograft rejection; and any combination thereof.

4. The method of claim 1 , wherein the bacteria strain is of the species Roseburia hominis.

5. The method of claim 1 , wherein the bacteria strain comprises a 16s rRNA gene sequence of SEQ ID NO:3.

6. The method of claim 1 , wherein the amount comprises from about 1×10 3 to about 1×10 11 CFU/g of the bacteria strain with respect to a total weight of the pharmaceutical composition.

7. The method of claim 1 , wherein the bacteria strain is in dried form.

8. The method of claim 1 , wherein the administering is oral administration.

9. The method of claim 4 , wherein the bacteria strain is a Roseburia hominis strain 433 deposited with the NCIMB under accession number NCIMB 42383.